avapro has been researched along with Disease Models, Animal in 81 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " ARB treatment ameliorates proteinuria in PAN nephropathy by inhibiting the reduction of NEPH1 and nephrin." | 7.80 | Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin. ( Fukusumi, Y; Kawachi, H; Kayaba, M; Kitazawa, Y; Takahashi, A; Tomita, M; Yamazaki, M, 2014) |
| "The objective of this study was to investigate the effects of irbesartan, carvedilol, and irbesartan plus carvedilol on the expression of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) mRNA and protein in rat myocardium after myocardial infarction (MI)." | 7.77 | Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction. ( Du, Y; Ge, Z; Liu, W; Yu, J; Zhao, J, 2011) |
| "To investigate the effects of carvedilol, irbesartan and their combination on myocardial collagen network remodeling after acute myocardial infarction (AMI) in rats." | 7.73 | [Experimental study of effect of carvedilol on myocardial collagen network remodeling after acute myocardial infarction in rats]. ( Bian, SY; Liu, HB; Wang, L; Yang, TS; Yang, X; Yi, J, 2005) |
| "Angiotensin II (Ang II) can induce cardiac fibrosis, but the underlying mechanisms are incompletely understood." | 7.72 | Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. ( Belloni, AS; Kreutz, R; Nussdorfer, GG; Paul, M; Pessina, AC; Rossi, GP; Seccia, TM, 2003) |
| "Diabetic spontaneously hypertensive rats developed albuminuria and had a reduction in both gene and protein expression of nephrin when compared with control rats." | 7.71 | Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. ( Allen, TJ; Boner, G; Bonnet, F; Cao, Z; Cooper, ME; Kawachi, H, 2001) |
| "Focal cerebral ischemia was induced by MCA occlusion for 2 hours followed by reperfusion for 22 hours." | 5.37 | Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats. ( Ahmad, SJ; Akhtar, M; Islam, F; Khanam, R; Pillai, KK; Pratap, R, 2011) |
| "We used a New Zealand white rabbit model of cationized bovine serum albumin (cBSA)-induced glomerulonephritis and then administered them metoprolol, irbesartan or acupuncture to evaluate the effectiveness of acupuncture treatment and preliminarily explore its potential mechanism." | 3.80 | "Qufeng Tongluo" acupuncture prevents the progression of glomerulonephritis by decreasing renal sympathetic nerve activity. ( An, P; Dang, HM; Shi, XM; Wu, XL; Ye, BY, 2014) |
| " ARB treatment ameliorates proteinuria in PAN nephropathy by inhibiting the reduction of NEPH1 and nephrin." | 3.80 | Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin. ( Fukusumi, Y; Kawachi, H; Kayaba, M; Kitazawa, Y; Takahashi, A; Tomita, M; Yamazaki, M, 2014) |
| " After surgery, the AAB-induced hypertension (AABIH) rats were treated with losartan 40 mg/kg/day, candesartan 10 mg/kg/day, irbesartan 10 mg/kg/day per os for 16 weeks." | 3.79 | Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats. ( Inamdar, MN; Kulkarni, C; Kulkarni, KS; Moinuddin, G, 2013) |
| "The objective of this study was to investigate the effects of irbesartan, carvedilol, and irbesartan plus carvedilol on the expression of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) mRNA and protein in rat myocardium after myocardial infarction (MI)." | 3.77 | Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction. ( Du, Y; Ge, Z; Liu, W; Yu, J; Zhao, J, 2011) |
| "For a given decrease in blood pressure, aliskiren improves coronary endothelial function and decreases cardiac hypertrophy in SHR to at least the same degree as ACE inhibition and AT1 receptor blockade." | 3.76 | Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. ( Bouhuizen, AM; Danser, AH; Garrelds, IM; Leijten, F; Moltzer, E; van Esch, JH; van Veghel, R, 2010) |
| " The aim of this study was to investigate the effect of an ACE-I (captopril) and an AT1R antagonist (irbesartan) in colorectal cancer liver metastases." | 3.74 | Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. ( Christophi, C; Malcontenti-Wilson, C; Muralidharan, V; Neo, JH, 2007) |
| "To investigate the effects of carvedilol, irbesartan and their combination on myocardial collagen network remodeling after acute myocardial infarction (AMI) in rats." | 3.73 | [Experimental study of effect of carvedilol on myocardial collagen network remodeling after acute myocardial infarction in rats]. ( Bian, SY; Liu, HB; Wang, L; Yang, TS; Yang, X; Yi, J, 2005) |
| "To observe effects of angiotensin (Ang) II receptor antagonist (AT1) irbesartan and angiotensin-converting enzyme (ACE) inhibitor perindopril on rat myocardium calcineurin expression and sarcoplasmic reticulum Ca(2+)-ATPase activity in the model of pressure-overload cardiac hypertrophy." | 3.73 | Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca2+-ATPase activity in rat cardiac pressure-overload hypertrophy. ( Jiang, QJ; Mao, FF; Xu, G; Zhu, YF, 2006) |
| "Angiotensin II (AII) has been shown to contribute to the pathogenesis of hypertension and insulin resistance." | 3.73 | Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats. ( Argentino, DP; Dominici, FP; Muñoz, MC; Toblli, JE; Turyn, D, 2006) |
| "Angiotensin II (Ang II) can induce cardiac fibrosis, but the underlying mechanisms are incompletely understood." | 3.72 | Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. ( Belloni, AS; Kreutz, R; Nussdorfer, GG; Paul, M; Pessina, AC; Rossi, GP; Seccia, TM, 2003) |
| "To determine the effects of the angiotensin II receptor antagonist irbesartan, the calcium-channel blocker amlodipine, and hydrochlorothiazide/hydralazine on superoxide, NAD(P)H oxidase and nitric oxide bioavailability in spontaneously hypertensive stroke-prone rats (SHRSP)." | 3.71 | Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. ( Brosnan, MJ; Dominiczak, AF; Graham, D; Hamilton, CA; Jardine, E; Lygate, CA, 2002) |
| "Diabetic spontaneously hypertensive rats developed albuminuria and had a reduction in both gene and protein expression of nephrin when compared with control rats." | 3.71 | Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. ( Allen, TJ; Boner, G; Bonnet, F; Cao, Z; Cooper, ME; Kawachi, H, 2001) |
| "Telmisartan is an angiotensin Type 1 (AT(1))-receptor antagonist being used in the treatment of hypertension." | 2.42 | Telmisartan - killing two birds with one stone. ( Doggrell, SA, 2004) |
| "Chronic heart failure is characterized as a clinical disorder by exercise intolerance." | 2.41 | Apoptosis and changes in contractile protein pattern in the skeletal muscle in heart failure. ( Ambrosio, GB; Dalla Libera, L; Vescovo, G, 2001) |
| "Candesartan is an insurmountable blocker with a slow dissociation from the AT1 receptor, and it has been shown to effectively reduce BP in humans and in a variety of genetic and experimental models of hypertension." | 2.40 | Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. ( Morsing, P, 1999) |
| " So, we investigated renal protective effects of SGLT2 inhibitor, dapagliflozin, alone and in combination with irbesartan in a rat model of diabetic nephropathy." | 1.48 | Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. ( Abdel-Wahab, AF; Al-Harizy, RM; Bamagous, GA; ElSawy, NA; Ghamdi, SSA; Ibrahim, IA; Shahzad, N, 2018) |
| "Sepsis is a systemic inflammatory response usually correlated with multi-organ failure." | 1.48 | Cardioprotective effects of irbesartan in polymicrobial sepsis : The role of the p38MAPK/NF-κB signaling pathway. ( Al-Amran, F; Hadi, NR; Yousif, NG; Zigam, QA, 2018) |
| " The blood samples were analyzed for various pharmacokinetic and pharmacodynamic parameters." | 1.46 | Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats. ( Anusha, A; Goverdhan, P; Krishna Murthy, B; Narendar, D, 2017) |
| "Leptin may cause delayed gastric emptying in the central and peripheral pathways." | 1.40 | Improved gastric emptying in diabetic rats by irbesartan via decreased serum leptin and ameliorated gastric microcirculation. ( He, L; Ren, R; Sun, Y; Wang, F; Zhang, Y; Zhu, Y, 2014) |
| " At the end of the follow-up, blood samples were taken for plasma lipid dosing and aorta samples for histology." | 1.38 | Anti-inflammatory drug evaluation in ApoE-/- mice by ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. ( Breisse, M; Canet-Soulas, E; Corot, C; Kaye, E; Lancelot, E; Majd, Z; Provost, N; Sigovan, M, 2012) |
| "Proteinuria was markedly attenuated in the sulodexide-treated groups." | 1.38 | Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure. ( Chen, XM; Li, P; Ma, LL; Wang, JZ; Wei, RB; Xie, RJ; Xie, YS; Yin, M, 2012) |
| "Focal cerebral ischemia was induced by MCA occlusion for 2 hours followed by reperfusion for 22 hours." | 1.37 | Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats. ( Ahmad, SJ; Akhtar, M; Islam, F; Khanam, R; Pillai, KK; Pratap, R, 2011) |
| "Atherosclerosis is a chronic inflammatory disease in which the renin-angiotensin-aldosterone system plays an important role." | 1.36 | Molecular mechanisms of irbesartan suppressing atherosclerosis in high cholesterol-diet apolipoprotein E knock-out mice. ( Chen, Y; Cheng, X; Ding, YJ; Liao, MY; Liao, YH; Tang, TT; Xie, JJ; Yao, R; Yu, X, 2010) |
| "Non-alcoholic steatohepatitis (NASH), which is a common liver disease in industrialized countries, is associated with obesity, hypertension, and type-2 diabetes (metabolic syndrome)." | 1.35 | ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. ( Cao, G; Mastai, R; Mella, J; Muñoz, MC; Pereyra, L; Toblli, JE, 2008) |
| " Additionally, we studied the effect of irbesartan on dose-response curves for the vasoconstriction induced by exogenous Ang II." | 1.32 | Sympatho-inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats. ( Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA, 2003) |
| " We compared the efficacy of an endothelin-receptor antagonist (darusentan), an angiotensin-receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide, HCTZ) to prevent and regress pulse pressure (PP) elevation and remodeling of large and small arteries, in a rat model of ISH obtained by the chronic administration of warfarin and vitamin K1 (WK)." | 1.31 | Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension. ( Dao, HH; De Champlain, J; Essalihi, R; Graillon, JF; Larivière, R; Moreau, P, 2002) |
| " In genetic and renal hypertensive rats, the antihypertensive effect induced after acute dosing of SR 47436 was similar to that observed after losartan and enalapril." | 1.29 | Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models. ( Canals, F; Cazaubon, C; Galindo, G; Lacour, C; Nisato, D; Segondy, D, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (4.94) | 18.2507 |
| 2000's | 30 (37.04) | 29.6817 |
| 2010's | 39 (48.15) | 24.3611 |
| 2020's | 8 (9.88) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Sawada, H | 1 |
| Ohno-Urabe, S | 1 |
| Ye, D | 1 |
| Franklin, MK | 1 |
| Moorleghen, JJ | 1 |
| Howatt, DA | 1 |
| Mullick, AE | 1 |
| Daugherty, A | 1 |
| Lu, HS | 1 |
| Zhou, T | 1 |
| Xie, Y | 1 |
| Hou, X | 1 |
| Bai, W | 1 |
| Li, X | 1 |
| Liu, Z | 1 |
| Man, Q | 1 |
| Sun, J | 1 |
| Fu, D | 1 |
| Yan, J | 1 |
| Zhang, Z | 1 |
| Wang, Y | 1 |
| Wang, H | 1 |
| Jiang, W | 1 |
| Gao, S | 1 |
| Zhao, T | 1 |
| Chang, A | 1 |
| Wang, X | 2 |
| Sun, H | 1 |
| Zhang, X | 1 |
| Yang, S | 1 |
| Huang, C | 1 |
| Hao, J | 1 |
| Liu, J | 1 |
| Hall, SE | 1 |
| Ahn, B | 1 |
| Smuder, AJ | 1 |
| Morton, AB | 1 |
| Hinkley, JM | 1 |
| Wiggs, MP | 1 |
| Sollanek, KJ | 1 |
| Hyatt, H | 1 |
| Powers, SK | 1 |
| Fang, LN | 1 |
| Zhong, S | 1 |
| Huang, LJ | 1 |
| Lu, B | 1 |
| Shen, LW | 1 |
| Tang, FY | 1 |
| Sun, HP | 1 |
| Zhang, L | 1 |
| Moser, AB | 1 |
| Liu, Y | 2 |
| Shi, X | 1 |
| Schrifl, U | 1 |
| Hiebler, S | 1 |
| Fatemi, A | 1 |
| Braverman, NE | 1 |
| Steinberg, SJ | 1 |
| Watkins, PA | 1 |
| Abdelhafez, AT | 1 |
| Gomaa, AMS | 1 |
| Ahmed, AM | 1 |
| Sayed, MM | 1 |
| Ahmed, MA | 1 |
| Nijiati, Y | 1 |
| Maimaitiyiming, D | 1 |
| Yang, T | 1 |
| Li, H | 2 |
| Aikemu, A | 1 |
| Li, S | 3 |
| Wang, K | 1 |
| Xu, G | 2 |
| Ji, J | 1 |
| Qin, C | 1 |
| Anusha, A | 1 |
| Narendar, D | 1 |
| Krishna Murthy, B | 1 |
| Goverdhan, P | 1 |
| Culman, J | 1 |
| Jacob, T | 1 |
| Schuster, SO | 1 |
| Brolund-Spaether, K | 1 |
| Brolund, L | 1 |
| Cascorbi, I | 1 |
| Zhao, Y | 1 |
| Gohlke, P | 1 |
| Li, L | 1 |
| Li, J | 1 |
| Yi, J | 2 |
| Liu, H | 1 |
| Lei, H | 1 |
| Abdel-Wahab, AF | 1 |
| Bamagous, GA | 1 |
| Al-Harizy, RM | 1 |
| ElSawy, NA | 1 |
| Shahzad, N | 1 |
| Ibrahim, IA | 1 |
| Ghamdi, SSA | 1 |
| Kabel, AM | 1 |
| Alzahrani, AA | 1 |
| Bawazir, NM | 1 |
| Khawtani, RO | 1 |
| Arab, HH | 1 |
| Mohamed, EA | 1 |
| Ahmed, HI | 1 |
| Zaky, HS | 1 |
| Ren, GD | 1 |
| -Y Cui, Y | 1 |
| Li, WL | 1 |
| Li, FF | 1 |
| Han, XY | 1 |
| Chilukoti, RK | 1 |
| Mostertz, J | 1 |
| Bukowska, A | 1 |
| Aderkast, C | 1 |
| Felix, SB | 1 |
| Busch, M | 1 |
| Völker, U | 1 |
| Goette, A | 1 |
| Wolke, C | 1 |
| Homuth, G | 1 |
| Lendeckel, U | 1 |
| Vignier, N | 1 |
| Le Corvoisier, P | 1 |
| Blard, C | 1 |
| Sambin, L | 1 |
| Azibani, F | 1 |
| Schlossarek, S | 1 |
| Delcayre, C | 1 |
| Carrier, L | 1 |
| Hittinger, L | 1 |
| Su, JB | 1 |
| Kusunoki, H | 1 |
| Taniyama, Y | 1 |
| Rakugi, H | 1 |
| Morishita, R | 1 |
| Moinuddin, G | 1 |
| Inamdar, MN | 1 |
| Kulkarni, KS | 1 |
| Kulkarni, C | 1 |
| Satoh, M | 2 |
| Nagasu, H | 1 |
| Haruna, Y | 1 |
| Ihoriya, C | 1 |
| Kadoya, H | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 2 |
| Linz, D | 1 |
| Mahfoud, F | 1 |
| Linz, B | 1 |
| Hohl, M | 1 |
| Schirmer, SH | 1 |
| Wirth, KJ | 1 |
| Böhm, M | 1 |
| Takenaka, T | 1 |
| Inoue, T | 1 |
| Ohno, Y | 1 |
| Miyazaki, T | 1 |
| Nishiyama, A | 1 |
| Ishii, N | 1 |
| Suzuki, H | 1 |
| An, P | 1 |
| Dang, HM | 1 |
| Shi, XM | 1 |
| Ye, BY | 1 |
| Wu, XL | 1 |
| He, L | 1 |
| Sun, Y | 1 |
| Zhu, Y | 1 |
| Ren, R | 1 |
| Zhang, Y | 1 |
| Wang, F | 1 |
| Takahashi, A | 1 |
| Fukusumi, Y | 1 |
| Yamazaki, M | 1 |
| Kayaba, M | 1 |
| Kitazawa, Y | 1 |
| Tomita, M | 1 |
| Kawachi, H | 2 |
| Hasegawa, Y | 1 |
| Nakagawa, T | 1 |
| Uekawa, K | 1 |
| Ma, M | 1 |
| Lin, B | 1 |
| Kusaka, H | 1 |
| Katayama, T | 1 |
| Sueta, D | 1 |
| Toyama, K | 2 |
| Koibuchi, N | 2 |
| Kim-Mitsuyama, S | 2 |
| Hayashi, M | 1 |
| Takeshita, K | 1 |
| Uchida, Y | 1 |
| Yamamoto, K | 1 |
| Kikuchi, R | 1 |
| Nakayama, T | 1 |
| Nomura, E | 1 |
| Cheng, XW | 1 |
| Matsushita, T | 1 |
| Nakamura, S | 1 |
| Murohara, T | 1 |
| Hayashi, K | 2 |
| Sasamura, H | 1 |
| Nakamura, M | 1 |
| Sakamaki, Y | 1 |
| Azegami, T | 1 |
| Oguchi, H | 1 |
| Tokuyama, H | 1 |
| Wakino, S | 1 |
| Itoh, H | 1 |
| Kataoka, N | 1 |
| Nishida, K | 1 |
| Kinoshita, K | 1 |
| Sakamoto, T | 1 |
| Nakatani, Y | 1 |
| Tsujino, Y | 1 |
| Mizumaki, K | 1 |
| Inoue, H | 1 |
| Kinugawa, K | 1 |
| Xing, G | 1 |
| Wei, M | 1 |
| Xiu, B | 1 |
| Ma, Y | 1 |
| Liu, T | 1 |
| Nakano, Y | 1 |
| Matoba, T | 1 |
| Tokutome, M | 1 |
| Funamoto, D | 1 |
| Katsuki, S | 1 |
| Ikeda, G | 1 |
| Nagaoka, K | 1 |
| Ishikita, A | 1 |
| Nakano, K | 1 |
| Koga, J | 1 |
| Sunagawa, K | 1 |
| Egashira, K | 1 |
| Zhong, J | 2 |
| Gong, W | 1 |
| Lu, L | 1 |
| Chen, J | 1 |
| Lu, Z | 1 |
| Liu, W | 2 |
| Wang, M | 1 |
| Hu, R | 1 |
| Long, H | 1 |
| Wei, L | 1 |
| Yousif, NG | 1 |
| Hadi, NR | 1 |
| Al-Amran, F | 1 |
| Zigam, QA | 1 |
| Jing, L | 1 |
| Li, WM | 1 |
| Zhou, LJ | 1 |
| Kou, JJ | 1 |
| Song, J | 1 |
| Yao, R | 1 |
| Cheng, X | 1 |
| Chen, Y | 1 |
| Xie, JJ | 1 |
| Yu, X | 1 |
| Liao, MY | 1 |
| Ding, YJ | 1 |
| Tang, TT | 1 |
| Liao, YH | 1 |
| Kassiri, Z | 1 |
| Guo, D | 1 |
| Basu, R | 1 |
| Liu, PP | 1 |
| Scholey, JW | 1 |
| Penninger, JM | 1 |
| Oudit, GY | 1 |
| Muñoz, MC | 3 |
| Giani, JF | 1 |
| Dominici, FP | 2 |
| Turyn, D | 2 |
| Toblli, JE | 3 |
| Moltzer, E | 2 |
| Verkuil, AV | 1 |
| van Veghel, R | 2 |
| Danser, AH | 2 |
| van Esch, JH | 2 |
| Sakuta, T | 1 |
| Morita, Y | 1 |
| Fox, DA | 1 |
| Pratap, R | 1 |
| Pillai, KK | 1 |
| Khanam, R | 1 |
| Islam, F | 1 |
| Ahmad, SJ | 1 |
| Akhtar, M | 1 |
| Garrelds, IM | 1 |
| Leijten, F | 1 |
| Bouhuizen, AM | 1 |
| Alexandru, N | 2 |
| Popov, D | 2 |
| Dragan, E | 2 |
| Andrei, E | 2 |
| Georgescu, A | 2 |
| Raupach, T | 1 |
| Lüthje, L | 1 |
| Kögler, H | 1 |
| Duve, C | 1 |
| Schweda, F | 1 |
| Hasenfuss, G | 1 |
| Andreas, S | 1 |
| Yu, J | 1 |
| Zhao, J | 1 |
| Ge, Z | 1 |
| Du, Y | 1 |
| Nakamura, T | 1 |
| Kataoka, K | 1 |
| Tokutomi, Y | 1 |
| Nako, H | 1 |
| Dong, YF | 1 |
| Yamamoto, E | 1 |
| Yasuda, O | 1 |
| Ogawa, H | 1 |
| Titorencu, I | 1 |
| Tarziu, C | 1 |
| Ghiorghe, S | 1 |
| Badila, E | 1 |
| Bartos, D | 1 |
| Li, P | 1 |
| Ma, LL | 1 |
| Xie, RJ | 1 |
| Xie, YS | 1 |
| Wei, RB | 1 |
| Yin, M | 1 |
| Wang, JZ | 1 |
| Chen, XM | 1 |
| Sigovan, M | 1 |
| Kaye, E | 1 |
| Lancelot, E | 1 |
| Corot, C | 1 |
| Provost, N | 1 |
| Majd, Z | 1 |
| Breisse, M | 1 |
| Canet-Soulas, E | 1 |
| Marut, W | 1 |
| Kavian, N | 1 |
| Servettaz, A | 1 |
| Hua-Huy, T | 1 |
| Nicco, C | 1 |
| Chéreau, C | 1 |
| Weill, B | 1 |
| Dinh-Xuan, AT | 1 |
| Batteux, F | 1 |
| Riveiro, A | 1 |
| Mosquera, A | 1 |
| Alonso, M | 1 |
| Calvo, C | 1 |
| Dao, HH | 1 |
| Essalihi, R | 1 |
| Graillon, JF | 1 |
| Larivière, R | 1 |
| De Champlain, J | 1 |
| Moreau, P | 1 |
| Balt, JC | 1 |
| Mathy, MJ | 1 |
| Pfaffendorf, M | 1 |
| van Zwieten, PA | 1 |
| Seccia, TM | 1 |
| Belloni, AS | 2 |
| Kreutz, R | 1 |
| Paul, M | 1 |
| Nussdorfer, GG | 2 |
| Pessina, AC | 2 |
| Rossi, GP | 2 |
| Pons, S | 1 |
| Hagège, A | 1 |
| Fornes, P | 1 |
| Gervais, M | 1 |
| Giudicelli, JF | 1 |
| Richer, C | 1 |
| Höcht, C | 2 |
| Opezzo, JA | 2 |
| Gironacci, M | 1 |
| Peña, C | 1 |
| Taira, CA | 2 |
| González-Albarrán, O | 1 |
| Gómez, O | 1 |
| Ruiz, E | 1 |
| Vieitez, P | 1 |
| García-Robles, R | 1 |
| Kowala, MC | 1 |
| Murugesan, N | 1 |
| Tellew, J | 1 |
| Carlson, K | 1 |
| Monshizadegan, H | 1 |
| Ryan, C | 1 |
| Gu, Z | 1 |
| Kane, B | 1 |
| Fadnis, L | 1 |
| Baska, RA | 1 |
| Beyer, S | 1 |
| Arthur, S | 1 |
| Dickinson, K | 1 |
| Zhang, D | 1 |
| Perrone, M | 1 |
| Ferrer, P | 1 |
| Giancarli, M | 1 |
| Baumann, J | 1 |
| Bird, E | 1 |
| Panchal, B | 1 |
| Yang, Y | 1 |
| Trippodo, N | 1 |
| Barrish, J | 1 |
| Macor, JE | 1 |
| Cao, B | 1 |
| Feng, QH | 1 |
| Li, XZ | 1 |
| Shimamura, T | 1 |
| Masui, M | 1 |
| Torii, M | 1 |
| Nakajima, M | 1 |
| Doggrell, SA | 1 |
| Liu, HB | 1 |
| Bian, SY | 1 |
| Yang, TS | 1 |
| Wang, L | 1 |
| Yang, X | 1 |
| Di Filippo, C | 1 |
| Lampa, E | 1 |
| Tufariello, E | 1 |
| Petronella, P | 1 |
| Freda, F | 1 |
| Capuano, A | 1 |
| D'Amico, M | 1 |
| Jiang, QJ | 1 |
| Mao, FF | 1 |
| Zhu, YF | 1 |
| Janiak, P | 1 |
| Bidouard, JP | 1 |
| Cadrouvele, C | 1 |
| Poirier, B | 1 |
| Gouraud, L | 1 |
| Grataloup, Y | 1 |
| Pierre, F | 1 |
| Bruneval, P | 1 |
| O'Connor, SE | 1 |
| Herbert, JM | 1 |
| Argentino, DP | 1 |
| Rakusan, K | 1 |
| Chvojkova, Z | 1 |
| Oliviero, P | 1 |
| Ostadalova, I | 1 |
| Kolar, F | 1 |
| Chassagne, C | 1 |
| Samuel, JL | 1 |
| Ostadal, B | 1 |
| Neo, JH | 1 |
| Malcontenti-Wilson, C | 1 |
| Muralidharan, V | 1 |
| Christophi, C | 1 |
| Fliegner, D | 1 |
| Westermann, D | 1 |
| Riad, A | 1 |
| Schubert, C | 1 |
| Becher, E | 1 |
| Fielitz, J | 1 |
| Tschöpe, C | 1 |
| Regitz-Zagrosek, V | 1 |
| Cao, G | 1 |
| Mella, J | 1 |
| Pereyra, L | 1 |
| Mastai, R | 1 |
| de Beer, VJ | 1 |
| Sorop, O | 1 |
| Pijnappels, DA | 1 |
| Dekkers, DH | 1 |
| Boomsma, F | 1 |
| Lamers, JM | 1 |
| Duncker, DJ | 1 |
| Merkus, D | 1 |
| Nussberger, J | 1 |
| Aubert, JF | 1 |
| Bouzourene, K | 1 |
| Pellegrin, M | 1 |
| Hayoz, D | 1 |
| Mazzolai, L | 1 |
| Lacour, C | 1 |
| Canals, F | 1 |
| Galindo, G | 1 |
| Cazaubon, C | 1 |
| Segondy, D | 1 |
| Nisato, D | 1 |
| Spinale, FG | 1 |
| Holzgrefe, HH | 1 |
| Walker, JD | 1 |
| Mukherjee, R | 1 |
| Kribbs, SB | 1 |
| Powell, JR | 1 |
| Antonaccio, M | 1 |
| Morsing, P | 1 |
| Hope, S | 1 |
| Brecher, P | 1 |
| Chobanian, AV | 1 |
| Vescovo, G | 1 |
| Ambrosio, GB | 1 |
| Dalla Libera, L | 1 |
| Bonnet, F | 1 |
| Cooper, ME | 1 |
| Allen, TJ | 1 |
| Boner, G | 1 |
| Cao, Z | 1 |
| Brosnan, MJ | 1 |
| Hamilton, CA | 1 |
| Graham, D | 1 |
| Lygate, CA | 1 |
| Jardine, E | 1 |
| Dominiczak, AF | 1 |
| Cavallin, M | 1 |
| Mazzocchi, G | 1 |
| Sartore, S | 1 |
3 reviews available for avapro and Disease Models, Animal
| Article | Year |
|---|---|
Telmisartan - killing two birds with one stone.
Topics: 3T3-L1 Cells; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl | 2004 |
Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1999 |
Apoptosis and changes in contractile protein pattern in the skeletal muscle in heart failure.
Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; Biphenyl Compounds; Contractile Proteins; Dise | 2001 |
78 other studies available for avapro and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Inhibition of the Renin-Angiotensin System Fails to Suppress β-Aminopropionitrile-Induced Thoracic Aortopathy in Mice-Brief Report.
Topics: Aminopropionitrile; Angiotensin II; Angiotensinogen; Animals; Aortic Aneurysm, Thoracic; Aortic Rupt | 2022 |
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Gemcitabine; Humans | 2023 |
Comparative Efficacy of Angiotensin II Type 1 Receptor Blockers Against Ventilator-Induced Diaphragm Dysfunction in Rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrophy; Diaphragm; Disease Models, Animal; Drug E | 2021 |
Protective Effect of Irbesartan by Inhibiting ANGPTL2 Expression in Diabetic Kidney Disease.
Topics: Angiopoietin-Like Protein 2; Angiopoietin-like Proteins; Animals; Cells, Cultured; Diabetic Nephropa | 2020 |
Drug discovery for X-linked adrenoleukodystrophy: An unbiased screen for compounds that lower very long-chain fatty acids.
Topics: Adrenoleukodystrophy; Animals; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily | 2021 |
Pioglitazone and/or irbesartan ameliorate COPD-induced endothelial dysfunction in side stream cigarette smoke-exposed mice model.
Topics: Animals; Antihypertensive Agents; Cigarette Smoking; Disease Models, Animal; Endothelium; Hypoglycem | 2021 |
Research on the improvement of oxidative stress in rats with high-altitude pulmonary hypertension through the participation of irbesartan in regulating intestinal flora.
Topics: Altitude Sickness; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Gastroi | 2021 |
The intervention effect of zinc supplementation on irbesartan treatment for atherosclerosis of ApoE-/- mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antioxidants; Aorta; Aor | 2016 |
Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Bio | 2017 |
Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2017 |
Dose-Effect of Irbesartan on Cyclooxygenase-2 and Matrix Metalloproteinase-9 Expression in Rabbit Atherosclerosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Atheroscle | 2018 |
Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Biphenyl Compounds; Blood Pressure; Body Weight; Diabetic | 2018 |
Targeting the proinflammatory cytokines, oxidative stress, apoptosis and TGF-β1/STAT-3 signaling by irbesartan to ameliorate doxorubicin-induced hepatotoxicity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibiotics, Antineoplastic; Apoptosis; Biphenyl C | 2018 |
Protective effect of irbesartan against doxorubicin-induced nephrotoxicity in rats: implication of AMPK, PI3K/Akt, and mTOR signaling pathways.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Blood Urea Nitrogen; Caspase 3; Creatinine; Di | 2018 |
Research on cardioprotective effect of irbesartan in rats with myocardial ischemia-reperfusion injury through MAPK-ERK signaling pathway.
Topics: Animals; Apoptosis; Cardiotonic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; He | 2019 |
Effects of irbesartan on gene expression revealed by transcriptome analysis of left atrial tissue in a porcine model of acute rapid pacing in vivo.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Biphenyl Comp | 2013 |
AT1 blockade abolishes left ventricular hypertrophy in heterozygous cMyBP-C null mice: role of FHL1.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Carrier Protei | 2014 |
Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Epithe | 2013 |
Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2013 |
Hypertension promotes islet morphological changes with vascular injury on pre-diabetic status in SHRsp rats.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Hydral | 2014 |
Effect of obstructive respiratory events on blood pressure and renal perfusion in a pig model for sleep apnea.
Topics: Aldosterone; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Disea | 2014 |
Calcitriol supplementation improves endothelium-dependent vasodilation in rat hypertensive renal injury.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Calcitriol; Di | 2014 |
"Qufeng Tongluo" acupuncture prevents the progression of glomerulonephritis by decreasing renal sympathetic nerve activity.
Topics: Acupuncture Therapy; Animals; Biphenyl Compounds; Disease Models, Animal; Disease Progression; Glome | 2014 |
Improved gastric emptying in diabetic rats by irbesartan via decreased serum leptin and ameliorated gastric microcirculation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Glucose; Diabetes Compli | 2014 |
Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Diseas | 2014 |
Therapy with the Combination of Amlodipine and Irbesartan Has Persistent Preventative Effects on Stroke Onset Associated with BDNF Preservation on Cerebral Vessels in Hypertensive Rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Bl | 2016 |
Angiotensin II receptor blocker ameliorates stress-induced adipose tissue inflammation and insulin resistance.
Topics: Adipokines; Adipose Tissue, White; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals | 2014 |
Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphe | 2015 |
Effect of irbesartan on development of atrial fibrosis and atrial fibrillation in a canine atrial tachycardia model with left ventricular dysfunction, association with p53.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Atrial Remodeling; Biphenyl C | 2016 |
[Irbesartan reduces inflammatory response of central nervous system in a rat model of fluid percussion brain injury].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Brain; Brain Injuries; Carbon | 2016 |
Nanoparticle-Mediated Delivery of Irbesartan Induces Cardioprotection from Myocardial Ischemia-Reperfusion Injury by Antagonizing Monocyte-Mediated Inflammation.
Topics: Administration, Intravenous; Animals; Biphenyl Compounds; Cardiotonic Agents; Disease Models, Animal | 2016 |
Irbesartan ameliorates hyperlipidemia and liver steatosis in type 2 diabetic db/db mice via stimulating PPAR-γ, AMPK/Akt/mTOR signaling and autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Autophagy; Biphenyl Compounds; Dia | 2017 |
Cardioprotective effects of irbesartan in polymicrobial sepsis : The role of the p38MAPK/NF-κB signaling pathway.
Topics: Animals; Cardiotonic Agents; Coinfection; Cytokines; Disease Models, Animal; Enzyme Activation; Hemo | 2018 |
Expression of renin-angiotensin system and peroxisome proliferator-activated receptors in alcoholic cardiomyopathy.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Bi | 2008 |
Molecular mechanisms of irbesartan suppressing atherosclerosis in high cholesterol-diet apolipoprotein E knock-out mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Bipheny | 2010 |
Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction.
Topics: Adaptation, Physiological; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; A | 2009 |
Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Glucose; Blo | 2009 |
Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation.
Topics: Analysis of Variance; Angiotensin II; Angiotensin III; Animals; Aorta, Abdominal; Biphenyl Compounds | 2010 |
Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arthritis, Experi | 2010 |
Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Aspirin; Biphenyl Compounds; Brain I | 2011 |
Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Angiotens | 2010 |
Platelet activation in hypertension associated with hypercholesterolemia: effects of irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; Biphenyl Co | 2011 |
Local and systemic effects of angiotensin receptor blockade in an emphysema mouse model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomechanical Phenomena; Biphenyl Compounds; Disea | 2011 |
Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction.
Topics: Adrenergic Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood | 2011 |
Novel mechanism of salt-induced glomerular injury: critical role of eNOS and angiotensin II.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Bipheny | 2011 |
Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Biphenyl Compounds; Blood Pressur | 2012 |
Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Biphenyl Compounds; Blood Pressure; Bl | 2012 |
Anti-inflammatory drug evaluation in ApoE-/- mice by ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Biphenyl Comp | 2012 |
Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Biphenyl Compoun | 2013 |
Angiotensin II type 1 receptor blocker irbesartan ameliorates vascular function in spontaneously hypertensive rats regardless of oestrogen status.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; | 2002 |
Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Arteries; Biphenyl Compounds; Calcinosis; Collage | 2002 |
Sympatho-inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats.
Topics: Adrenergic alpha-Agonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting | 2003 |
Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Biphenyl Compounds; | 2003 |
Effects of angiotensin II type 1 receptor blockade in ApoE-deficient mice with post-ischemic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Biphenyl Comp | 2003 |
Study of the hypothalamic angiotensin system in aortic coarctated rats using the reverse microdialysis technique.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor | 2003 |
Role of systolic blood pressureon the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity, and hypertension (Zucker rats).
Topics: Albuminuria; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus | 2003 |
Pharmacokinetics and the cardiovascular effects of irbesartan in aortic coarctated rats.
Topics: Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Aorta; Aortic Coarctation; Bipheny | 2004 |
Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood | 2004 |
[Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antibiotics, Antineoplastic; Biphenyl Com | 2003 |
Hypotensive and prophylactic effects of angiotensin II subtype 1 receptor antagonist, irbesartan, in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Biphenyl Comp | 2004 |
[Experimental study of effect of carvedilol on myocardial collagen network remodeling after acute myocardial infarction in rats].
Topics: Animals; Biphenyl Compounds; Carbazoles; Carvedilol; Collagen; Disease Models, Animal; Hemodynamics; | 2005 |
Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Ce | 2005 |
Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca2+-ATPase activity in rat cardiac pressure-overload hypertrophy.
Topics: Animals; Biphenyl Compounds; Calcineurin; Calcium-Transporting ATPases; Cardiomegaly; Disease Models | 2006 |
Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Glucose; Blood Pressure; | 2006 |
Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats.
Topics: Adaptor Proteins, Signal Transducing; Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Re | 2006 |
ANG II type 1 receptor antagonist irbesartan inhibits coronary angiogenesis stimulated by chronic intermittent hypoxia in neonatal rats.
Topics: Altitude; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Arterioles; Biphenyl C | 2007 |
Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl | 2007 |
Up-regulation of PPARgamma in myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; CD36 Antigens; | 2008 |
ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2008 |
Integrative control of coronary resistance vessel tone by endothelin and angiotensin II is altered in swine with a recent myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Coronary Circu | 2008 |
Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
Topics: Amides; Amlodipine; Animals; Antihypertensive Agents; Apolipoproteins E; Atenolol; Atherosclerosis; | 2008 |
Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; | 1994 |
Angiotensin II subtype-1 receptor blockade during the development of left ventricular hypertrophy in dogs: effects on ventricular and myocyte function.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1997 |
Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1999 |
Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Di | 2001 |
Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aort | 2002 |
Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Geneticall | 2002 |